Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy

[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]

[Immunotherapy and malignant mesothelioma: clinical perspectives]

Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells

Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells

[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]

Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma

Localised spontaneous regression in mesothelioma — possible immunological mechanism